Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 12/01 03:59:44 pm
134.725 EUR   +0.65%
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partnerships
DJ
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
MD
11/26MERCK : Partners With Siemens on New Plant
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Launches Cell and Gene Therapy Platform

10/13/2020 | 09:28am EST

By Cecilia Butini

Merck KgaA said Tuesday that it has launched a platform for the development of cell and gene therapies.

The German pharmaceutical and chemicals company said the platform, which is named VirusExpress, focuses on the production of lentiviruses as viral vectors, or vectors used to carry genetic material into cells, with a therapeutic goal.

According to the company, the technology allows for the reduction of processing development time and for increases in the cell dose available for patient use for each batch of virus.

Merck added that VirusExpress can be licensed flexibly so that companies can manufacture vectors using Merck's contract manufacturing capability, third-party contract development or in-house development.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

10-13-20 0927ET

All news about MERCK KGAA
02:45aMERCK : to Accelerate Commercialization of OLED Display Materials Through Partne..
DJ
11/30MERCK KGAA : Gets a Buy rating from Kepler Cheuvreux
MD
11/26MERCK : Partners With Siemens on New Plant
DJ
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
More news
Financials
Sales 2020 17 381 M 20 800 M 20 800 M
Net income 2020 2 013 M 2 409 M 2 409 M
Net Debt 2020 11 224 M 13 432 M 13 432 M
P/E ratio 2020 28,7x
Yield 2020 1,05%
Capitalization 58 195 M 69 553 M 69 644 M
EV / Sales 2020 3,99x
EV / Sales 2021 3,71x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 133,85 €
Spread / Highest target 26,3%
Spread / Average Target 1,13%
Spread / Lowest Target -24,5%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA27.05%69 553
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD90.24%19 173
KYOWA KIRIN CO., LTD.10.18%14 594
BETTA PHARMACEUTICALS CO., LTD.38.95%5 594
YUHAN CORPORATION36.15%3 641
RECIPHARM AB (PUBL)29.21%1 996